Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). [electronic resource]
Producer: 20030116Description: 995-1002 p. digitalISSN:- 1097-6744
- Acetates -- therapeutic use
- Acute Disease
- Aged
- Anticoagulants -- therapeutic use
- Coronary Disease -- drug therapy
- Data Interpretation, Statistical
- Drug Therapy, Combination
- Female
- Heparin -- therapeutic use
- Heparin, Low-Molecular-Weight -- therapeutic use
- Humans
- Male
- Middle Aged
- Myocardial Revascularization
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Randomized Controlled Trials as Topic
- Survival Analysis
- Tyrosine -- analogs & derivatives
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.